Posted by Michael Wonder on 19 Oct 2022
Pembrolizumab for adjuvant treatment of adults with renal cell carcinoma
19 October 2022 - NICE has published evidence-based recommendations on the use of pembrolizumab for the adjuvant treatment of adults with renal cell carcinoma.
Pembrolizumab is recommended as an option for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence after nephrectomy, with or without metastatic lesion resection.
It is recommended only if Merck/MSD provides it according to the commercial arrangement.
